Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 74,599 | 46,881 | 66,182 | 114,947 | 137,468 |
| Marketable Securities | 158,532 | 184,486 | 193,012 | 146,811 | 143,934 |
| Receivables | 14,119 | 4,881 | 6,358 | 4,505 | 6,044 |
| Income taxes - deferred | N/A | 1,943 | 1,937 | 1,937 | 1,937 |
| TOTAL | $254,139 | $244,623 | $273,510 | $273,309 | $293,534 |
| Non-Current Assets | |||||
| PPE Net | 18,289 | 18,399 | 18,554 | 18,304 | 18,324 |
| Investments And Advances | 120,389 | 140,523 | 138,907 | 162,541 | 160,349 |
| Intangibles | 448 | 491 | 535 | 578 | 622 |
| Other Non-Current Assets | 0 | 8,570 | 8,674 | 8,674 | 8,556 |
| TOTAL | $139,126 | $167,983 | $166,670 | $190,097 | $187,851 |
| Total Assets | $393,265 | $412,606 | $440,180 | $463,406 | $481,385 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,312 | 6,561 | 10,398 | 6,988 | 12,489 |
| Accrued Expenses | 11,116 | 10,880 | 7,425 | 8,754 | 9,961 |
| TOTAL | $102,046 | $99,433 | $102,033 | $98,571 | $110,733 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 81,618 | 81,755 | 83,938 | 82,731 | 82,767 |
| Other Non-Current Liabilities | 143 | 0 | 168 | 181 | 194 |
| TOTAL | $132,986 | $152,530 | $172,669 | $193,005 | $192,687 |
| Total Liabilities | $235,032 | $251,963 | $274,702 | $291,576 | $303,420 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 42,344 | 42,200 | 42,097 | 41,961 | 41,837 |
| Common Shares | 423 | 422 | 421 | 419 | 418 |
| Retained earnings | -343,347 | -336,417 | -326,787 | -312,155 | -299,832 |
| Other shareholders' equity | 714 | 1,288 | 1,286 | 823 | 716 |
| TOTAL | $158,233 | $160,643 | $165,478 | $171,830 | $177,965 |
| Total Liabilities And Equity | $393,265 | $412,606 | $440,180 | $463,406 | $481,385 |